Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors

NCT05585320 is registered in ClinicalTrials.gov with Immuneering Corporation as lead sponsor.

NCT NCT05585320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05585320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
Immuneering Corporation
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 31, 2022
Completion date
June 30, 2027
Enrollment
209 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, malignant melanoma (cutaneous), non-small cell lung cancer (nsclc), pancreatic adenocarcinoma